Sandbox Reserved 390: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
Line 10: Line 10:
The interplay between the <scene name='Sandbox_Reserved_390/Top/6'>protein</scene>, the <scene name='Sandbox_Reserved_390/Top/5'>DNA</scene>, and the drug explains the structure-activity relations of etoposide derivatives and the molecular basis of drug-resistant mutations.  
The interplay between the <scene name='Sandbox_Reserved_390/Top/6'>protein</scene>, the <scene name='Sandbox_Reserved_390/Top/5'>DNA</scene>, and the drug explains the structure-activity relations of etoposide derivatives and the molecular basis of drug-resistant mutations.  


Also, at the <scene name='Sandbox_Reserved_390/Top/1'>active site</scene> we can see the <scene name='Sandbox_Reserved_390/Top/7'>ligand</scene>, and both <scene name='Sandbox_Reserved_390/Top/3'>alpha helices</scene>, and <scene name='Sandbox_Reserved_390/Top/2'>beta sheets</scene> at the <scene name='Sandbox_Reserved_390/Top/4'>secondary structures</scene>.  
Also, at the <scene name='Sandbox_Reserved_390/Top/1'>active site</scene> we can see the <scene name='Sandbox_Reserved_390/Top/7'>ligand</scene>, and both <scene name='Sandbox_Reserved_390/Top/3'>alpha helices</scene>, and <scene name='Sandbox_Reserved_390/Top/2'>beta sheets</scene> of the <scene name='Sandbox_Reserved_390/Top/4'>secondary structures</scene>.  
<!-- PLEASE ADD YOUR CONTENT BELOW HERE -->
<!-- PLEASE ADD YOUR CONTENT BELOW HERE -->



Revision as of 17:35, 19 September 2012

Human topoisomerase IIbeta in complex with DNA and etoposide

Insert caption here

Drag the structure with the mouse to rotate


Crystal structure of a large fragment of human type II topoisomerases (TOP2) complexed to DNA and to the anticancer drug etoposide to reveal structural details of drug-induced stabilization of a cleavage complex[1].

The interplay between the protein, the DNA, and the drug explains the structure-activity relations of etoposide derivatives and the molecular basis of drug-resistant mutations.

Also, at the active site we can see the ligand, and both alpha helices, and beta sheets of the secondary structures.


References

  1. ↑ Wu CC, Li TK, Farh L, Lin LY, Lin TS, Yu YJ, Yen TJ, Chiang CW, Chan NL. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science. 2011 Jul 22;333(6041):459-62. PMID:21778401 doi:10.1126/science.1204117